Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Prostate cancer: does genetic score justify early prostate biopsy?

Sugihara T, Kattan MW.

Nat Rev Urol. 2013 Nov;10(11):628-9. doi: 10.1038/nrurol.2013.238. Epub 2013 Oct 22. No abstract available.

PMID:
24145474
2.

Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.

Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G.

J Urol. 2002 Aug;168(2):483-7.

PMID:
12131293
3.

[Prospective evaluation of prostate cancer screening in men with a family history of the disease].

Paiss T, Herkommer K, Kahn D, Gschwend JE, Küfer R, Maier C, Vogel W, Högel J, Hautmann RE.

Urologe A. 2006 Aug;45(8):1002-5. German.

PMID:
16830128
4.

Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?

Butoescu V, Ambroise J, Stainier A, Dekairelle AF, Gala JL, Tombal B.

Prostate. 2014 Apr;74(4):365-71. doi: 10.1002/pros.22757. Epub 2013 Nov 22.

PMID:
24265090
5.

Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J.

Eur Urol. 2013 Mar;63(3):585-7. doi: 10.1016/j.eururo.2012.11.047. Epub 2012 Dec 5. No abstract available.

6.

[Prostate cancer, generalized screening soon?].

Girault V.

Presse Med. 2002 Aug 10;31(26):1205. French. No abstract available.

PMID:
12212509
7.

Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).

Kirby RS, Fitzpatrick JM, Irani J.

BJU Int. 2009 Feb;103(4):441-5. doi: 10.1111/j.1464-410X.2008.08280.x. Epub 2009 Jan 9. Review.

8.

Genetics: susceptibility loci in a molecular subtype of prostate cancer.

Klein RJ.

Nat Rev Urol. 2009 Jul;6(7):357-8. doi: 10.1038/nrurol.2009.108. No abstract available.

PMID:
19578351
9.

HPC2 variants and screen-detected prostate cancer.

Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA.

Am J Hum Genet. 2001 Apr;68(4):912-7. Epub 2001 Mar 14.

10.

[The prostate: new genetic data on cancer].

Nau JY.

Rev Med Suisse. 2008 Feb 20;4(145):489. French. No abstract available.

PMID:
18376529
11.

Screening for prostate cancer in high risk populations.

Catalona WJ, Antenor JA, Roehl KA, Moul JW.

J Urol. 2002 Nov;168(5):1980-3; discussion 1983-4.

PMID:
12394689
12.

Utility of incorporating genetic variants for the early detection of prostate cancer.

Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, Punnen S, Venkateswaran V, Toi A, Loblaw DA, Sugar L, Siminovitch KA, Narod SA.

Clin Cancer Res. 2009 Mar 1;15(5):1787-93. doi: 10.1158/1078-0432.CCR-08-1593. Epub 2009 Feb 17.

13.

Prostate cancer risk-associated genetic markers and their potential clinical utility.

Xu J, Sun J, Zheng SL.

Asian J Androl. 2013 May;15(3):314-22. doi: 10.1038/aja.2013.42. Epub 2013 Apr 8.

14.

Genetic predisposition to early recurrence in clinically localized prostate cancer.

Borque Á, del Amo J, Esteban LM, Ars E, Hernández C, Planas J, Arruza A, Llarena R, Palou J, Herranz F, Raventós CX, Tejedor D, Artieda M, Simon L, Martínez A, Carceller E, Suárez M, Allué M, Sanz G, Morote J.

BJU Int. 2013 Apr;111(4):549-58. doi: 10.1111/j.1464-410X.2012.11333.x. Epub 2012 Jul 3.

15.

A review of targeted screening for prostate cancer: introducing the IMPACT study.

Mitra AV, Bancroft EK, Eeles RA; IMPACT Steering Committee and Collaborators.

BJU Int. 2007 Jun;99(6):1350-5. Epub 2007 Apr 5. Review. No abstract available. Erratum in: BJU Int. 2007 Sep;100(3):718-9.

16.

[Association of a positive family history with histopathology and clinical course in early-onset prostate cancer].

Herkommer K, Paiss T, Merz M, Gschwend JE, Kron M.

Urologe A. 2006 Dec;45(12):1532-9. German.

PMID:
17004091
17.

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.

Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.

Prostate. 2013 Feb 15;73(3):242-9. doi: 10.1002/pros.22563. Epub 2012 Jul 20.

PMID:
22821767
18.

Risk factors, prevention and early detection of prostate cancer.

Loeb S, Schaeffer EM.

Prim Care. 2009 Sep;36(3):603-21. doi: 10.1016/j.pop.2009.04.007.

PMID:
19616157
19.

BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland.

Ikonen T, Matikainen MP, Syrjäkoski K, Mononen N, Koivisto PA, Rökman A, Seppälä EH, Kallioniemi OP, Tammela TL, Schleutker J.

J Med Genet. 2003 Aug;40(8):e98. No abstract available.

20.

[Genetics of prostate cancer].

Thomas F, Jaïs P, Cohen-Akenine A.

Bull Cancer. 2001 Mar;88(3):287-94. French.

PMID:
11313206
Items per page

Supplemental Content

Write to the Help Desk